217 related articles for article (PubMed ID: 37958189)
1. A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis.
Guarischi-Sousa R; Kroll JE; Bonaldi A; Pierry PM; Villela D; Souza CA; Silva JS; Bürger MC; Oliveira FA; de Paula MG; Meliso FM; de Almeida LG; Monfredini PM; de Oliveira AG; Milanezi F; Scapulatempo-Neto C; Yamamoto GL
Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958189
[TBL] [Abstract][Full Text] [Related]
2. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
[TBL] [Abstract][Full Text] [Related]
3. In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study.
Pepe F; Guerini-Rocco E; Fassan M; Fusco N; Vacirca D; Ranghiero A; Venetis K; Rappa A; Taormina SV; Russo G; Rebellato E; Munari G; Moreno-Manuel A; De Angelis C; Zamagni C; Valabrega G; Malapelle U; Troncone G; Barberis M; Iaccarino A
J Clin Pathol; 2023 Apr; ():. PubMed ID: 37072171
[TBL] [Abstract][Full Text] [Related]
4. Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer.
Fountzilas E; Papadopoulou K; Chatzikonstantinou T; Karakatsoulis G; Constantoulakis P; Tsantikidi A; Tsaousis G; Karageorgopoulou S; Koumarianou A; Mauri D; Ntavatzikos A; Saridaki Z; Petrakis G; Fostira F; Fountzilas G; Liontos M
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067228
[TBL] [Abstract][Full Text] [Related]
5. Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
Magliacane G; Brunetto E; Calzavara S; Bergamini A; Pipitone GB; Marra G; Redegalli M; Grassini G; Rabaiotti E; Taccagni G; Pecciarini L; Carrera P; Mangili G; Doglioni C; Cangi MG
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612041
[TBL] [Abstract][Full Text] [Related]
6. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR
Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253
[TBL] [Abstract][Full Text] [Related]
7. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Ngoi NYL; Tan DSP
ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
[TBL] [Abstract][Full Text] [Related]
8. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
9. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.
Pfarr N; von Schwarzenberg K; Zocholl D; Merkelbach-Bruse S; Siemanowski J; Mayr EM; Herold S; Kleo K; Heukamp LC; Willing EM; Menzel M; Lehmann U; Bartels S; Chakraborty S; Baretton G; Demes MC; Döring C; Kazdal D; Budczies J; Rad R; Wild P; Christinat Y; McKee T; Schirmacher P; Horst D; Büttner R; Stenzinger A; Sehouli J; Vollbrecht C; Hummel M; Braicu EI; Weichert W;
JCO Precis Oncol; 2024 Mar; 8():e2300348. PubMed ID: 38513168
[TBL] [Abstract][Full Text] [Related]
10. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
11. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
12. Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches.
Mangogna A; Munari G; Pepe F; Maffii E; Giampaolino P; Ricci G; Fassan M; Malapelle U; Biffi S
J Pers Med; 2023 Feb; 13(2):. PubMed ID: 36836518
[TBL] [Abstract][Full Text] [Related]
13. Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Roma C; Esposito Abate R; Sacco A; Califano D; Arenare L; Bergantino F; Pisano C; Cecere SC; Scambia G; Lorusso D; Artioli G; Tasca G; Spina A; Russo D; Gadducci A; De Angelis C; Bologna A; Marchini S; Capoluongo ED; Perrone F; Pignata S; Normanno N
Eur J Cancer; 2024 May; 206():114127. PubMed ID: 38797038
[TBL] [Abstract][Full Text] [Related]
14. Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
Kang J; Na K; Kang H; Cho U; Kwon SY; Hwang S; Lee A
PLoS One; 2024; 19(3):e0298128. PubMed ID: 38527014
[TBL] [Abstract][Full Text] [Related]
15. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Capoluongo ED; Pellegrino B; Arenare L; Califano D; Scambia G; Beltrame L; Serra V; Scaglione GL; Spina A; Cecere SC; De Cecio R; Normanno N; Colombo N; Lorusso D; Russo D; Nardelli C; D'Incalci M; Llop-Guevara A; Pisano C; Baldassarre G; Mezzanzanica D; Artioli G; Setaro M; Tasca G; Roma C; Campanini N; Cinieri S; Sergi A; Musolino A; Perrone F; Chiodini P; Marchini S; Pignata S
ESMO Open; 2022 Oct; 7(5):100585. PubMed ID: 36156447
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
17. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
18. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
19. CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study.
Zouzoulas D; Tsolakidis D; Tzitzis P; Chatzistamatiou K; Theodoulidis V; Sofianou I; Grimbizis G; Timotheadou E
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791269
[TBL] [Abstract][Full Text] [Related]
20. [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
Pfarr N; Merkelbach-Bruse S
Pathologe; 2021 Jul; 42(4):391-398. PubMed ID: 34152463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
